在急性髓性白血病中可测量的残留病导疗法:实用见解
Boaz Nachmias1, Arnon Haran1, Meira Yisraeli Salman2
1Leukemia Service, Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
British journal of haematology
|August 31, 2025
概括
在急性髓性白血病 (AML) 治疗中,可测量的残留病 (MRD) 监测至关重要. 这篇评论探讨了MRD
科学领域:
- 血液学
- 癌症学
- 分子诊断
背景情况:
- 可测量的残留病 (MRD) 是急性髓性白血病 (AML) 的关键预后指标.
- 准确的MRD评估对于预测患者的结果和指导治疗调整至关重要.
研究的目的:
- 审查各种AML遗传亚组中MRD的预后意义.
- 评估MRD在治疗决策中的作用,包括预防性治疗,干细胞移植和维持策略.
主要方法:
- 对最近的研究和AMLMRD评估的新趋势进行了批判性评估.
- 分析MRD对治疗策略和临床决策的影响.
主要成果:
- 在不同AML遗传特征中具有预后价值.
- 有证据表明MRD会影响预防性治疗和干细胞移植的决策.
结论:
- 在反洗钱管理中,MRD是一个不断发展的决策工具.
- 需要进一步的随机试验来巩固MRD指导的治疗方案,并优化个性化护理.
更多相关视频
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.1K
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
261
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...